TARA · Protara Therapeutics, Inc.
$2.73
+0.08 (+2.83%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$156.60M
Shares
59.10M
Volume · Oct 9
670.08K
Avg daily vol (3M)
810.53K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.65
Open$2.59
Day$2.52–2.69
52W close$2.56–7.56
Avg vol 30d1.3M
Short int4.4M · 7.5% float · 10.3d
Short vol53%
Last earningsMay 13, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 11
Up next
Next earnings call
May 13, 2028
Est · unconfirmed
· in 83 wks
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$70.02M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-257.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+44.3%
Year over year · more shares
Price change (1Y)
-47.7%
Trailing year
Short interest
7.5%
Latest settlement · 10.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−45%
below
Price vs 50-day avg
−28%
below
RSI (14)
23
oversold
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−30%
trailing
6-month return
−51%
trailing
YTD return
−50%
this year
Relative strength
−60%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Distributing
3 of 119 funds reported for Sep 30 · net -154 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.47% of float · ▼ -0.3% MoM · 10.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
119 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
EPS growth
+38%
Y/Y
Free cash flow
$-56.5M
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−45%
Bearish
Price vs 50-day avg
−28%
Bearish
RSI (14)
23
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Distributing
3 of 119 funds reported for Sep 30 · net -154 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.47% of float · ▼ -0.3% MoM · 10.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
119 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $3 · 2%
Range high $8
vs 200-day avg -45%
vs 50-day avg -28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| unrestricted cash and cash equivalents and marketable debt securities | $161.9M | second quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TARA
this stock
Protara Therapeutics, Inc.
|
$156.60M | -50.3% | — | — | 7.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.55B | +11.0% | +46.2% | 29.3 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.3 | 2.5% |
|
CSLLY
Csl Ltd
|
$61.58B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TARA | -4.0% | -30.1% | -51.3% | -13.1% | -50.3% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -5.3% | -32.2% | -60.3% | -14.6% | -63.8% |